The second session about Clinical use of TDM of biologics in different pathologies just came to an end with a good panel discussion. The session had a great kick-start with Sjoerd Repping about Good use of expensive drug.
Denis Mulleman then shared his experience in creating a Network for TDM of biologics in European cooperation in science and technology.
One biologic for multiple diseases, multiple biologics in one disease that is the approach that Floris Loeff shared with us.
Before we had the panel discusion then Rob ter Heine shared the do’s and don’ts on TDM of biologics in oncology.
The third session is about to start. Talking about Deeper understanding of the PK of biologics. Stay tuned!
This event is endorsed by International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and made possible by gold sponsor Takeda and silver sponsors AstraZeneca, Dr. Falk Pharma Benelux b.v., Fresenius Kabi, Johnson & Johnson, Pfizer, Sanofi and Theradiag.
Floris Loeff, Mark Löwenberg, Gertjan Wolbink, Anouk Wagenaar, Geert DHaens, Zoé van Kempen, Ron Mathôt, Phyllis Spuls, Theo Rispens, Annick de Vries, Kim Dijkman are there for you!
Reade – revalidatie & reumatologie, Sanquin, Amsterdam UMC
#biotherapeutics #bioanalysis #biologics
You can find more details and event video in the link below:
https://www.linkedin.com/feed/update/urn:li:activity:7007006589903589376/
